Ritu Parna Chakrabarti, MD
Hematology, Medical Oncology
Headshot of Ritu Parna Chakrabarti, MD

Ritu Parna Chakrabarti, MD

Hematology, Medical Oncology
Accepting new patients
Sees patients age 18 and up
Rena Rowan Breast Center
Headshot of Ritu Parna Chakrabarti, MD
Penn Medicine Provider

About me

  • Assistant Professor of Clinical Medicine (Hematology-Oncology)

My education and training

  • Saint George's University School of MedicineMedical School
  • Jersey City Medical Center, Rutgers HealthResidency
  • Jersey Shore Medical CenterFellowship

Spoken languages

English
English

Insurance accepted

Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.

Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Dr. Chakrabarti is a Penn Medicine provider.

Qualifications and experience

All conditions and treatments

Research

Publications

Jacob S, Li F, Sacksith K, Lee K, Chakrabarti R, Jankowitz R, Taranto E, Knollman H, Makhlin I, Clark AS, Shash PD, DeMichele A, Apostolidis S Changes in Patient Reported Outcomes Associated with Immune-related Toxicity: Interim Analysis from a Prospective Cohort of Locally Advanced TNBC Receiving Neoadjuvant Chemoimmunotherapy , 2026 San Antonio Breast Cancer Symposium: 2026


Jacob S, Li F, Sacksith K, Lee K, Chakrabarti R, Jankowitz R, Taranto E, Knollman H, Makhlin I, Clark AS, Shash PD, DeMichele A, Apostolidis S Early Peripheral CD8+ T-Cell Dynamics Associated With Immune-Related Toxicity: Interim Analysis From a Prospective Cohort of Locally Advanced TNBC Receiving Neoadjuvant Chemo-immunotherapy , 2026 San Antonio Breast Cancer Symposium: 2026


Chakrabarti R, Siegel D, Biran N. The Evolving Role of Checkpoint Inhibitors in Multiple Myeloma , Clin Lymphoma Myeloma Leuk: 2025


Chakrabarti, R., DeRosairo A, Peters S, Patel D, Tariq F, Abdulaaima M, Desai A, Jain D, Shanbhogue, D. Incidence of AKI and Clinical Outcomes in Patients Hospitalized with COVID-19 , J Gen Intern Med.: 2021


Chakrabarti R, Abdulaaima M, Gaiazov S, Shah A, Tharakan J, Tharakan K, Patel A. A look at the Immune Response to COVID-19 in Cancer Patients: Incidence of SARS-CoV2 IgG Antibodies Among Cancer Patients in a Hematology-oncology Clinic. , Oncolytics Today: 2021


Heaton J, Okoh AK, Sossou C, Singh S, Sandhu M, Chakrabarti R, Rao R, Waxman S, Tayal R, Wasty N. Adverse Events After Left Atrial Appendage Closure: Lessons Learned From the Manufacturer and User Facility Device Experience (MAUDE) Database , J Invasive Cardiol: 2020